the future of glp 1 drugs GLP-1 Market Trends and Global Forecasts Report 2025: A Beyond GLP-1: the next wave

If your insurance requires you to use a specific specialty pharmacy, your provider will route the prescription accordingly

Mitchell JL, Mollan SP, Vijay V, Sinclair AJ

The Duel for Dominance Zepbounds Dual Efficacy: Eli Lillys Zepbound (tirzepatide) entered the market with clinical trial results showing superior weight loss percentages compared to semaglutide (Wegovy)

Large-scale commercial compounding of semaglutide and tirzepatide has been restricted, and the FDA has pursued enforcement actions against operations outside compliant compounding frameworks

Analysts project sustained high growth: one market report forecasts GLP-1 sales will more than double from the mid-2020s into the 2030s ( [36] )

In the 1990s, researchers studying the Gila monster (Heloderma suspectum), a venomous lizard native to the southwestern United States and northwestern Mexico, made a groundbreaking discovery that would transform diabetes treatment